Trial results

Tirzepatide for Treatment of CCCA

NCT07734870 on ClinicalTrials.gov · last registry update 2026-09-23

A small phase 2 — 20 participants, against a typical 110. Due to report 25 May 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score. Sponsors move these dates routinely; any movement since this site started watching is listed below. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P2

Drug

tirzepatide

Mounjaro, Zepbound

Sponsor

Johns Hopkins University

Sponsor type

Other

Enrollment

20

Started

2026-09-15

Primary completion

2028-05-25 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score

Conditions studied

Central Centrifugal Cicatricial Alopecia (CCCA)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.